Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

531
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
531
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

33
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
33
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

54
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
54
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

54
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
54
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

26
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
26
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

68
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
68

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment.

Frontiers in pharmacology·2026
Same author

Quantitative systems pharmacology model of B cell immune response in mouse.

Frontiers in immunology·2026
Same author

Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.

Pharmaceutics·2026
Same author

Multiscale physiologically-based model of age-dependent CD4+ T-lymphocyte homeostasis.

Frontiers in immunology·2026
Same author

A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.

Clinical pharmacology and therapeutics·2025

相关实验视频

Updated: May 21, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

1.9K

量化系统药理学模型执行的框架

Victor Sokolov1,2, Kirill Peskov3,4,5, Gabriel Helmlinger6

  • 1M&S Decisions FZ LLC, Dubai, UAE. victor.sokolov@msdecisions.tech.

Handbook of experimental pharmacology
|March 20, 2025
PubMed
概括

本章概述了药物开发的定量系统药理 (QSP) 建模工作流程. 它详细介绍了使用普通微分方程的模型开发,校准和模拟方面的挑战.

关键词:
模型开发 模型开发模型验证模型验证基于模型的模拟.建模工作流程的工作流程.量化系统药理学 药理学

更多相关视频

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
00:05

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

13.8K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

140

相关实验视频

Last Updated: May 21, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

1.9K
In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
00:05

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

13.8K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

140

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 计算生物学 计算生物学
  • 数学建模的数学建模

背景情况:

  • 数学模型近似观察到的模式,指导新药的研究和开发,特别是剂量-暴露-反应关系.
  • 量化系统药理 (QSP) 模型以机械学方式描述生物系统和治疗干预措施.

研究的目的:

  • 提供QSP建模工作流程的全面概述.
  • 突出QSP模型开发,校准和解释中的挑战.
  • 为新手和经验丰富的QSP建模人员提供资源.

主要方法:

  • 使用普通微分方程作为模型构建的中心框架.
  • 整合系统的文献审查和选择适当的结构模型方程.
  • 执行系统行为分析,模型资格和各种基于模型的模拟.

主要成果:

  • QSP模型的开发需要整合现有知识和多样化的数据集,平衡复杂性和不确定性.
  • 数据稀缺,特别是在人类受试者层面,使QSP模型校准变得复杂,需要早期敏感性分析.
  • 基于模型的预测必须仔细与基础数据和数学方法保持一致.

结论:

  • QSP建模工作流包括定义,合格和模拟模型,根据目标进行变化.
  • 解决QSP中的挑战需要对生理学和先进的参数估计技术有深入的了解.
  • 描述的工作流提供了实施QSP方法的实际指导和资源.